REG - Adv Medical Solutns. - Full Year 2025 Trading Update

Advanced Medical SolutionsAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260115:nRSO9445Oa&default-theme=true

RNS Number : 9445O  Advanced Medical Solutions Grp PLC  15 January 2026

15 January 2026

 

Advanced Medical Solutions Group plc

("AMS" or the "Group")

 

Full Year 2025 Trading Update
 

~ Strong growth in line with expectations, driven by key surgical product
categories ~

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the innovative
tissue-healing medical device company delivering high-performing solutions for
better patient outcomes, today announces a trading update for the twelve
months ended 31 December 2025.

The Group expects to report full year 2025 revenues of approximately £228.5
million (2024: £177.5 million), EBITDA of £49.5 - £50.0 million (2024:
£40.2 million), and the Board is confident of meeting market expectations.
Its performance was driven by continued strong growth across key surgical
product categories and a good recovery in its Woundcare business, offsetting
some elements of destocking in the Peters Surgical B2B business.

 

The integration of Peters Surgical and Syntacoll remains on track. Commercial
synergies contributed positively during the year with operational synergies
are on track to be realised during 2027 onwards.

 

Notice of Results:

The Group intends to announce its full year results for the year ended 31
December 2025 on 18 March 2026.

 

Chris Meredith, Chief Executive Officer of AMS, said: "Our surgical business
has recorded another period of strong performance, and we have also benefited
from the restructuring of our woundcare franchise. Our portfolio is now
broader and stronger than at any point in the Group's history, and our
pipeline includes a number of exciting and significant opportunities for
future growth. The integration of Peters Surgical has accelerated the
expansion of our geographic footprint, and our plans for further penetration
into the US market are well advanced. We remain confident in delivering
another strong performance in 2026 and over the long-term, supported by the
sustained momentum across the business."

 

- End -

 

For further information, please visit www.admedsol.com
(http://www.admedsol.com) or contact:

 

 Advanced Medical Solutions Group plc       Tel: +44 (0) 1606 545508
 Chris Meredith, Chief Executive Officer

 Eddie Johnson, Chief Financial Officer

 Michael King, Investor Relations

 Optimum Strategic Communications           Tel: +44 (0) 20 4566 8543
 Mary Clark / Nick Bastin / Isabelle Abdou  AMS@optimumcomms.com

 Investec Bank PLC (NOMAD & Broker)         Tel: +44 (0) 20 7597 5970
 Gary Clarence / David Anderson

 Berenberg (Joint Broker)                   Tel: +44 (0)20 3207 7800
 Toby Flaux / Detlir Elezi

 

About Advanced Medical Solutions Group plc - see www.admedsol.com
(http://www.admedsol.com)

AMS is an innovative tissue healing medical device company delivering
high-performing solutions that match or surpass market leaders, clinically,
technically, and commercially. From adhesives and sealants, to biosurgical
devices and sutures, AMS's products offer superior usability, quality and
design. AMS's strength lies in combining advanced material science with
applicator device design and development, in collaboration with surgeons and
Key Opinion Leaders, creating differentiated devices that improve patient
outcomes without compromising quality or affordability.

 

AMS's scalable, resilient business model is built on disciplined execution,
portfolio focus, and capital efficiency. Its diversified product and
geographic mix mitigates volatility, ensuring consistent performance even when
individual segments fluctuate. Following its acquisition of Peters Surgical,
AMS is unlocking operational and commercial synergies, accelerating its U.S.
and international expansion, and increasing the percentage of sales made
through its direct sales teams. With surgical products driving the lion's
share of group revenues and a clear top-line trajectory, AMS is positioned for
scalable growth, margin improvement, and long-term value creation.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTBIMRTMTBBBTF



            Copyright 2019 Regulatory News Service, all rights reserved